Marc Goldberg

Marc Goldberg co-founded BioVentures Investors with Peter Feinstein, forming its first fund in 1998. Previously, Marc served as President and CEO of the Massachusetts Biotechnology Research Institute, from 1991 to 1997. During his tenure, MBRI raised $20 million in funding and was responsible for the launch of 24 new companies, including Phytera, t-Breeders (ViaCell), Acusphere and Eligix. From 1987 to 1991, Marc was Vice President, Finance and Corporate Development, CFO, and Treasurer at Safer, Inc., a developer and manufacturer of biopesticides and related products. Before Safer, he was Manager, Business Development at Genetics Institute, one of the earliest biotechnology companies. Marc served four terms as the President of the Massachusetts Biotechnology Council, of which he was Founding President, and as a Director from its inception in 1985 to 1997. He is currently a member of the Harvard Medical School Neuroscience Advisory Committee and served as a member of the Beth Israel Deaconess Medical Center Board of Directors Research Advisory Committee. He has served on the Board of Directors of Applied Spine, Ardais, BioValve, Enanta, AngioLink, Verax Biomedical, Cardiosolutions, Claros Diagnostics, HydroCision, New Chemical Entities, sGC Pharma, Spirus Medical, Rachiotek, Pintex and Vital Sensors. Marc earned his A.B. from Harvard College, his J.D. from Harvard Law School, and his M.B.A. from Harvard Business School.